Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label, Multicenter, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered KT-621 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT06945458 is registered in ClinicalTrials.gov with Kymera Therapeutics, Inc. as lead sponsor.

NCT NCT06945458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06945458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label, Multicenter, Single-arm Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered KT-621 in Adult Participants With Moderate to Severe Atopic Dermatitis
Lead sponsor
Kymera Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 17, 2025
Completion date
November 10, 2025
Enrollment
22 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis